Drug profile

The FDA adverse-event record for Thiabendazole/Dexamethasone/Neomycin

15 FDA reports name Thiabendazole/Dexamethasone/Neomycin, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2120 of 2,679
by report volume (all drugs)
15
adverse-event reports
6.7%
death-coded share
Cat
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Thiabendazole/Dexamethasone/Neomycin ranks #2072 of 2679 by total reports (15). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2072
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Thiabendazole/Dexamethasone/Neomycin has 15 reports now versus 15 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Thiabendazole/Dexamethasone/Neomycin changes

Signature read: 15 reports place Thiabendazole/Dexamethasone/Neomycin in the lower third of FDA AER volume (#2120 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
1
Deaths Reported
6.7%
Death-coded share of reports

Active Ingredients

Thiabendazole/Dexamethasone/Neomycin

Administration Routes

UnknownAuricular (Otic)Topical

Species Affected

Cat 10
Dog 5

Most Affected Breeds

Domestic Shorthair 8
Domestic Longhair 2
Crossbred Canine/dog 1
Shepherd Dog - German 1
Poodle - Standard 1
Retriever - Labrador 1
Terrier - Boston 1

Most Reported Reactions

Application site alopecia 3
Ataxia 3
Vomiting 3
Vocalisation 3
Head shake - ear disorder 3
Pruritus 2
Inappetence 2
Head tilt - ear disorder 2
Diarrhoea 2
Inappropriate urination 2
Ear infection NOS 2
Urinary tract infection 2

Outcome Breakdown

Outcome Unknown
8 (53.3%)
Recovered/Normal
6 (40.0%)
Died
1 (6.7%)

Thiabendazole/Dexamethasone/Neomycin: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Thiabendazole/Dexamethasone/Neomycin (#2120 of 2,679 by report volume); death-coded 6.7%. PlainBreed drug row · report volume stamp 15 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →